Morgan Stanley
MS
$188.65
-1.26%
Morgan Stanley is a global financial services firm operating in the Financial - Capital Markets industry, providing a comprehensive suite of services including investment banking, institutional trading, wealth management, and asset management. The company is a dominant market leader, distinguished by its massive wealth and asset management franchises, which now generate the lion's share of its income and manage over $9.3 trillion in client assets. The current investor narrative is heavily focused on the firm's ability to capitalize on market volatility, as evidenced by recent headlines highlighting a record-breaking trading quarter driven by geopolitical tensions, while ongoing debate centers on the sustainability of its diversified model in shifting interest rate and capital markets environments.…
MS
Morgan Stanley
$188.65
Related headlines
Investment Opinion: Should I buy MS Today?
Rating & Thesis: Hold. Morgan Stanley is a high-quality franchise with a powerful wealth management engine, but near-term execution risks and balance sheet concerns offset its strengths, suggesting the stock is fairly valued at current levels. The limited analyst data shows a bullish lean, but without a clear average target, the implied upside is ambiguous.
Supporting Evidence: The hold rating is supported by a reasonable forward PE of 15.11x, which prices in stable earnings but not aggressive growth. Profitability is strong with a net margin of 14.66% and ROE of 15.10%. However, these are counterbalanced by alarming negative FCF of -$17.89B and high financial leverage (D/E of 4.26). The stock's 72.94% 1-year gain also suggests much of the positive narrative may already be reflected in the price, trading near its 52-week high.
Risks & Conditions: The two biggest risks are the persistence of negative free cash flow and a deceleration in revenue growth below 10% YoY. This Hold would upgrade to a Buy if the company demonstrates a clear path to generating sustained positive FCF while maintaining its ROE above 14%. It would downgrade to a Sell if revenue growth turns negative or the debt-to-equity ratio climbs above 5.0. Valuation Verdict: The stock appears fairly valued relative to its own earnings trajectory and sector positioning, trading at a modest premium justified by its leading franchise but not offering a clear margin of safety.
Sign up to view all
MS 12-Month Price Forecast
The outlook is one of high-quality stability with embedded financial risk. The firm's premier franchises provide a solid earnings floor, but the balance sheet and cash flow statements reveal underlying strain that limits upside potential in the near term. The base case of range-bound trading is most likely, as the market grapples with these cross-currents. The stance would upgrade to Bullish on clear evidence of a return to sustainable positive free cash flow and a reduction in financial leverage. It would downgrade to Bearish if the next quarterly report shows a further deterioration in FCF or a material slowdown in wealth management net new assets.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $245.25 and implied upside of +30.0% versus the current price.
Average Target
$245.25
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$151 - $245
Analyst target range
Analyst coverage for Morgan Stanley is limited in the provided dataset, with only 7 analysts tracked, which is lower than typical for a mega-cap financial institution, suggesting the data may be incomplete. The consensus sentiment, inferred from recent institutional ratings, leans bullish with firms like Barclays and Keefe, Bruyette & Woods maintaining 'Overweight'/'Outperform' ratings, while JP Morgan holds a 'Neutral' stance; however, a precise consensus recommendation and average target price are not available in the data, preventing a calculated implied upside/downside. The target price range is also not provided, but the recent rating actions show a pattern of reiterations rather than significant upgrades or downgrades, indicating steady analyst conviction. The implication of potentially limited visible coverage (based on the provided num_analysts: 7) is unusual for a firm of this size and may point to data gaps; in reality, broad coverage would typically lead to efficient price discovery, but incomplete data here limits the strength of the consensus signal.
Bulls vs Bears: MS Investment Factors
The evidence presents a balanced but cautiously optimistic picture, with the bull side holding a slight edge due to demonstrated earnings power, a premier franchise, and reasonable valuation. The most critical tension in the investment debate is the clash between the firm's robust profitability and recurring fee income versus its alarming negative free cash flow and high financial leverage. The resolution of this tension—specifically, whether the negative FCF is a temporary result of strategic balance sheet management or a structural concern—will be the primary determinant of the stock's ability to sustain its current valuation premium and uptrend.
Bullish
- Record Trading Quarter from Volatility: Recent news highlights a record-breaking $5.15 billion trading quarter driven by geopolitical volatility, showcasing the firm's ability to capitalize on market dislocations. This demonstrates the strength and resilience of its diversified banking and trading model, directly boosting near-term earnings.
- Strong Wealth & Asset Management Franchise: The firm manages over $9.3 trillion in client assets, with wealth management generating the largest segment revenue of $8.43B in Q4 2025. This provides a stable, high-margin, and recurring fee-based income stream that is less volatile than pure investment banking or trading revenues.
- Robust Profitability and Margins: Q4 2025 net income was $4.40B with a net margin of 14.66% and a gross margin of 58.02%. The firm maintains a high Return on Equity (ROE) of 15.10%, indicating efficient use of shareholder capital to generate profits.
- Attractive Valuation with Forward PE Discount: The stock trades at a forward PE of 15.11x, a discount to its trailing PE of 16.54x, suggesting the market is pricing in stable earnings. The PEG ratio of 0.58, based on trailing metrics, indicates the stock may be undervalued relative to its earnings growth rate.
Bearish
- Severe Negative Free Cash Flow: Trailing twelve-month free cash flow is deeply negative at -$17.89B, indicating heavy reliance on financing for operations and capital allocation. This raises concerns about financial flexibility and the sustainability of shareholder returns if the trend persists.
- High Financial Leverage: The firm carries a debt-to-equity ratio of 4.26, indicating significant financial leverage. This amplifies risks during economic downturns or periods of rising interest rates, as fixed interest expenses consume a larger portion of operating income.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 11.08% YoY to $28.86B, this marks a sequential decline from Q3 2025 revenue of $30.05B. This deceleration suggests potential headwinds or cyclical moderation in key business segments like institutional securities or wealth management.
- Valuation Premium and Cyclical Sensitivity: The stock's Price-to-Book (PB) ratio of 2.50x represents a significant premium to book value. Combined with a beta of 1.182 (18% more volatile than the market), the stock is susceptible to sharp pullbacks if financial sector sentiment sours or earnings growth falters.
MS Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +72.94%. With a current price of $188.82, it is trading at approximately 86% of its 52-week range ($104.78 to $194.59), positioning it near the upper bounds and signaling strong momentum, though also raising questions about potential overextension. Recent momentum shows a significant divergence, with a powerful 1-month surge of +18.81% sharply contrasting with a slight 3-month decline of -0.14%; this suggests the stock experienced a meaningful pullback in Q1 2026 before a vigorous recovery in April, potentially indicating a resumption of the primary uptrend. Key technical support is anchored at the 52-week low of $104.78, while immediate resistance sits at the 52-week high of $194.59; a decisive breakout above this level would confirm bullish strength, whereas a failure could lead to consolidation. The stock's beta of 1.182 indicates it is approximately 18% more volatile than the broader market (SPY), which is a critical consideration for risk management given its recent price swings and a maximum drawdown of -20.26% over the observed period.
Beta
1.18
1.18x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$111-$195
Price range past year
Annual Return
+68.0%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | +13.7% | +8.5% |
| 3m | +5.4% | +2.8% |
| 6m | +15.1% | +4.6% |
| 1y | +68.0% | +32.3% |
| ytd | +3.7% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue growth remains healthy but shows signs of sequential deceleration; Q4 2025 revenue was $28.86 billion, representing a solid 11.08% year-over-year increase, yet this marks a decline from the $30.05 billion reported in Q3 2025. Segment data reveals a balanced contribution, with the Wealth Management Segment leading at $8.43 billion, followed by Institutional Securities at $7.93 billion and Investment Management at $1.72 billion. The company is highly profitable, with Q4 2025 net income of $4.40 billion and a robust net margin of 14.66%; gross margin for the quarter was a strong 58.02%, though it has fluctuated between 54.7% and 58.7% over the past year, indicating relative stability in core profitability. Balance sheet health requires careful scrutiny; while the firm boasts a solid Return on Equity (ROE) of 15.10%, it carries significant financial leverage with a debt-to-equity ratio of 4.26. More concerning is the trailing twelve-month free cash flow, which is deeply negative at -$17.89 billion, primarily due to substantial debt repayment and investment activities in recent quarters, indicating heavy reliance on financing and balance sheet management to fund operations and capital allocation.
Quarterly Revenue
$28.9B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$-17.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given a positive net income of $4.40 billion, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 16.54x, while the forward PE is slightly lower at 15.11x; this modest discount suggests the market anticipates stable, but not dramatically accelerating, earnings growth. Compared to sector averages, Morgan Stanley's valuation presents a mixed picture; its trailing PE of 16.54x and Price-to-Sales (PS) ratio of 2.43x are not directly comparable to a generic industry average from the provided data, but its Price-to-Book (PB) ratio of 2.50x indicates a significant premium to book value, typical for a firm with high-return, fee-based businesses like wealth management. Historically, the stock's current trailing PE of 16.54x sits well above its own multi-year low observed in recent quarters (e.g., ~10.7x in Q1 2025) but is also below peaks seen during periods of lower profitability, suggesting the current multiple prices in improved earnings but is not at extreme historical highs, balancing optimism with some cyclical moderation.
PE
16.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on balance sheet strength and cash generation. The deeply negative TTM free cash flow of -$17.89B is a major red flag, indicating the firm is consuming far more cash than it generates from operations, likely due to substantial debt repayment and investments. This heavy reliance on external financing is exacerbated by a high debt-to-equity ratio of 4.26, which increases interest expense burden and vulnerability to credit market disruptions. Furthermore, while revenue grew 11.08% YoY in Q4, the sequential decline from Q3 suggests earnings visibility may be lower than the stable wealth management narrative implies.
Market & Competitive Risks stem from valuation compression and cyclicality. Trading at a PB ratio of 2.50x, the stock carries a premium that requires sustained high returns on equity, which could compress if capital markets activity weakens. The stock's beta of 1.182 confirms it is 18% more volatile than the market, making it susceptible to sector-wide sell-offs during risk-off periods. Competitive risks include pressure on wealth management fees and the cyclical nature of investment banking and trading revenues, as evidenced by the recent record quarter being tied to specific geopolitical volatility that may not be repeatable.
Worst-Case Scenario involves a simultaneous downturn in capital markets and a loss of client assets in wealth management, triggering a sharp decline in fee income while leverage magnifies the earnings drop. This could lead to credit rating concerns, forcing asset sales or a dilutive capital raise. Realistic downside could see the stock re-testing its 52-week low of $104.78, which represents a potential loss of approximately -45% from the current price of $188.82. The historical maximum drawdown of -20.26% over the observed period provides a more moderate, but still significant, risk benchmark.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Deeply negative free cash flow (-$17.89B TTM) and high debt-to-equity (4.26) threaten financial flexibility. 2) Cyclical Risk: Revenue is tied to capital markets and wealth sentiment; a downturn could sharply reduce earnings. The stock's beta of 1.182 confirms this volatility. 3) Execution Risk: Sequential revenue decline from Q3 to Q4 2025 suggests growth may be decelerating. 4) Valuation Risk: Trading near 52-week highs, any earnings miss could trigger a multiple compression given the premium PB ratio of 2.50x.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $175 and $195, as the company executes steadily but grapples with balance sheet concerns. The Bull Case (25% probability) targets $194 to $210, requiring a return to positive FCF and sustained capital markets strength. The Bear Case (15% probability) warns of a drop to $105-$150 in a severe downturn where leverage amplifies losses. The most likely outcome is the Base Case, hinging on the assumption that negative FCF is a temporary, managed phase rather than a structural problem.
MS appears fairly valued. Its forward PE of 15.11x is a discount to its trailing PE of 16.54x, indicating the market expects stable, not explosive, growth. The PEG ratio of 0.58 suggests undervaluation relative to historical growth, but this metric may be distorted by the negative FCF situation. The Price-to-Book ratio of 2.50x commands a premium, justified by its high-return wealth management business but leaving little room for error. Overall, the valuation implies the market is paying a fair price for a strong but financially leveraged company with mixed cash flow signals.
MS is a Hold, not a clear-cut buy at current levels. For investors already holding, it represents a quality franchise. For new money, the risk/reward is balanced. The stock has surged 72.94% over the past year, suggesting much optimism is priced in. While the forward PE of 15.11x is reasonable, the severe negative free cash flow of -$17.89B and high leverage pose significant risks. It could be a good buy for long-term investors on a meaningful pullback (e.g., towards $170) who believe management will successfully navigate the balance sheet challenges.
MS is more suitable for a long-term investment horizon of 3+ years. Its value is tied to the multi-year compounding of its massive wealth management asset base, not short-term trading gains. The stock's high beta (1.182) and recent 20.26% max drawdown make it volatile and risky for short-term trading. Furthermore, it pays a modest dividend (yield ~2.36%), which contributes to total return over time. Short-term traders would be betting on quarterly earnings beats or market volatility, while long-term investors are betting on the durability of the franchise and management's ability to improve the balance sheet.